How many biosimilars have been approved in the United States?

The number of biosimilars currently approved by the FDA is nineteen.

The most recent approval was Eticovo (etanercept-ykro) on April 25, 2019.

What is a biosimilar?
According the to FDA, a biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Avastin (bevacizumab) Biosimilars

• Mvasi (bevacizumab-awwb)

Enbrel (etanercept) Biosimilars

• Erelzi (etanercept-szzs)
• Eticovo (etanercept-ykro)

Epogen / Procrit (epoetin alfa) Biosimilars

• Retacrit (epoetin alfa-epbx)

Herceptin (trastuzumab) Biosimilars

• Ogivri (trastuzumab-dkst)
• Herzuma (trastuzumab-pkrb)
• Ontruzant (trastuzumab-dttb)
• Trazimera (trastuzumab-qyyp)

Humira (adalimumab) Biosimilars

• Amjevita (adalimumab-atto)
• Cyltezo (adalimumab-adbm)
• Hyrimoz (adalimumab-adaz)

Neulasta (pegfilgrastim) Biosimilars

• Fulphila (pegfilgrastim-jmdb)
• Udenyca (pegfilgrastim-cbqv)

Neupogen (filgrastim) Biosimilars

• Zarxio (filgrastim-sndz)
• Nivestym (filgrastim-aafi)

Remicade (infliximab) Biosimilars

• Inflectra (infliximab-dyyb)
• Renflexis (infliximab-abda)
• Ixifi (infliximab-qbtx)

Rituxan (rituximab) Biosimilars

• Truxima (rituximab-abbs)

More information: What Are Biosimilars? Top Facts You May Not Know